United States v. Medoff

Court of Appeals for the First Circuit·Decided November 18, 2025·No. 24-1750·Published

Opinion

United States Court of Appeals For the First Circuit

No. 24-1750 UNITED STATES OF AMERICA, Appellee,

v.

CRAIG MEDOFF,

Defendant, Appellant.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

[Hon. Mark L. Wolf, U.S. District Judge]

Before

Montecalvo, Howard, and Aframe, Circuit Judges.

Amy Barsky, with whom Fick & Marx LLP was on brief, for appellant.

Donald C. Lockhart, Assistant United States Attorney, with whom Leah B. Foley, United States Attorney, was on brief, for appellee.

November 18, 2025

AFRAME, Circuit Judge. In 2016, following approximately four years of litigation in a civil securities fraud enforcement action brought by the Securities and Exchange Commission ("SEC"), defendant-appellant Craig Medoff agreed to the entry of a judgment that, for ten years, barred him and any entity he owned or controlled "from participating in the issuance, offer, or sale of any security."

In 2024, Medoff pleaded guilty to criminal contempt of this judgment, see 18 U.S.C. § 401(3); Fed. R. Crim. P. 42(a), and was sentenced to twenty months of imprisonment, a variance of ten months above the top of the applicable guidelines sentencing range ("GSR"). He now seeks vacatur of his sentence on two grounds. He principally argues that the sentencing judge should have recused himself from presiding over the criminal contempt proceeding because his impartiality might reasonably have been questioned. See 28 U.S.C. § 455(a). Alternatively, he contends that his sentence was procedurally and substantively unreasonable. We reject his arguments and affirm.

I.

Medoff has a long history of violating federal securities laws and being involved in related criminal and civil proceedings. We provide a detailed account of this history to place Medoff's recusal arguments in context. The following facts are undisputed.

A.

On September 7, 1993, Medoff settled an SEC civil enforcement action, brought in the Southern District of New York, that charged him and the company of which he was president with fraudulently offering unregistered securities. In settling the case, Medoff consented to the entry of a permanent injunction that barred him from violating the anti-fraud provisions of the federal securities laws; required him to pay a civil penalty of $95,500; and ordered him to disgorge money he had obtained through his fraudulent conduct. On January 6, 1995, in a related administrative action, Medoff also agreed to an offer of settlement that barred him from associating with any securities broker, dealer, investment advisor, investment company, or municipal securities dealer. Medoff neither paid the civil fine nor complied with the disgorgement order. Nor, as we shall see, did he abide by the terms of the prohibitory orders that regulated his conduct with respect to securities.

On April 26, 1995, in a criminal action that was also instituted in the Southern District of New York, Medoff pleaded guilty to a sealed information charging him with two counts of conspiracy to commit fraud in connection with the offer and sale of securities. On October 20, 2009, more than fourteen years after his guilty plea, Medoff was sentenced to three years of probation and a $6,000 fine, which he did not fully pay. From 2011 to 2014,

Medoff was twice incarcerated for a total of about seventeen months on probation violations for failing drug tests and not making payments towards the fine.

B.

On December 14, 2012, while Medoff's troubles in the Southern District of New York were ongoing, the SEC instituted a civil enforcement action in the District of Massachusetts against Medoff; Biochemics, Inc. ("Biochemics"); and two additional individuals. The complaint alleged, among other things, that Medoff had participated in a fraudulent scheme to sell Biochemics securities to investors. It also highlighted the 1993 and 1995 judicial and regulatory orders that barred Medoff from violating the antifraud provisions of the federal securities laws and associating with any securities broker, dealer, investment advisor, investment company, or municipal securities dealer. The case was assigned to then-Chief Judge Wolf.

On March 18, 2015, the SEC submitted a proposed consent judgment for defendant Biochemics to the district court. The judgment contained language stating that the company would have to pay a substantial fine and disgorgement order within fourteen days of its entry. The court rejected this proposed judgment, apparently because all parties agreed that Biochemics would be unable to pay the disgorgement order and fine within the short

time specified. The court stated that it would not issue an order that it did not intend to enforce.

A few days later, on March 25, 2015, the district court entered a revised judgment for defendant Biochemics that obligated the company to disgorge $17,147,884 (including prejudgment interest) and to pay a civil penalty of $750,000. The revised judgment contained a schedule requiring payment of the fine within seven months and thereafter requiring payment of the disgorgement order, with interest, in five consecutive monthly payments. Biochemics paid the fine but did not make any of the disgorgement payments. During the litigation that ensued, the court repeatedly reiterated its unwillingness to issue orders that it did not intend to enforce.

On May 25, 2016, the district court entered a final consent judgment against Medoff that, for a period of ten years, prohibited him and any entity that he owned or controlled "from participating in the issuance, offer, or sale of any security." The judgment also ordered Medoff to pay a $100,000 civil penalty and to disgorge $14,370.20 (including prejudgment interest). As in the Southern District of New York litigation, Medoff did not satisfy any of these obligations.

On September 27, 2023, the SEC sought an order for Medoff to show cause why he should not be held in civil contempt for failing to comply with the 2016 consent judgment. In a memorandum

supporting its motion, the SEC stated that, in violation of the 2016 consent judgment, since at least 2021, Medoff "had involvement with, and likely ownership and/or control of, a financial services company . . . [named] Nova Capital International LLC" ("Nova Capital"). The SEC attached to its memorandum affidavits and exhibits supporting its allegations about Medoff's involvement with Nova Capital and detailing Medoff's history of securities fraud and non-compliance with court orders. It requested, among other things, an order directing Medoff to cease violating the 2016 consent judgment and to disgorge all money earned through its violation. It also requested "[a]n order imposing such other sanctions as the Court deems appropriate, including additional civil penalties, to ensure Medoff's future compliance."

On October 13, 2023, the district court issued a responsive memorandum and order stating that the SEC had provided "ample evidence to justify the initiation" of civil contempt proceedings. The court also stated that the SEC's evidence "raises the question of whether it would be appropriate for the court to initiate criminal contempt proceedings instead." The court elaborated: "In view of Medoff's proven history of violating court orders, conducting proceedings that could only result in another order that could be violated might be futile. Therefore, [a] civil remedy may be inappropriate and criminal contempt proceedings may be justified."

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Medoff, (1st Cir. 2025).

United States v. Medoff (United States v. Medoff) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Yates v. United States
355 U.S. 66 (Supreme Court, 1957)
Shillitani v. United States
384 U.S. 364 (Supreme Court, 1966)
Codispoti v. Pennsylvania
418 U.S. 506 (Supreme Court, 1974)
Liteky v. United States
510 U.S. 540 (Supreme Court, 1994)
Caperton v. A. T. Massey Coal Co., Inc.
556 U.S. 868 (Supreme Court, 2009)
United States v. Marquardo
149 F.3d 36 (First Circuit, 1998)
United States v. Pulido
566 F.3d 52 (First Circuit, 2009)
In Re United States of America
666 F.2d 690 (First Circuit, 1981)
United States v. Clogston
662 F.3d 588 (First Circuit, 2011)
In Re: Boston's Children First
244 F.3d 164 (First Circuit, 2001)
United States v. Caramadre
807 F.3d 359 (First Circuit, 2015)
United States v. Montero-Montero
817 F.3d 35 (First Circuit, 2016)
United States v. Torres-Estrada
817 F.3d 376 (First Circuit, 2016)
Williams v. Pennsylvania
579 U.S. 1 (Supreme Court, 2016)
United States v. Diaz-Lugo
963 F.3d 145 (First Circuit, 2020)
United States v. Reyes-Barreto
24 F.4th 82 (First Circuit, 2022)
In re United States
158 F.3d 26 (First Circuit, 1998)
United States v. Flores-Nater
62 F.4th 652 (First Circuit, 2023)
United States v. Feliciano-Candelario
128 F.4th 5 (First Circuit, 2025)